Lozano et al., instead, observed an increased pretreatment diversity of the TCR repertoire in a cohort of metastatic melanoma patients treated with anti-PD-1 monotherapy or anti-PD-1 and anti-CTLA-4 combination ICIs, who developed severe irAEs (19). This evidence concerns the gene CTLA4 and metastatic melanoma.